The DOI matches its OpenAlex record; 35 of the 35 references it cites were found in a registry or an index.
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Open accessAbstract
Paclitaxel concentrations in the brain are very low after intravenous injection. Since paclitaxel is excluded from some tumors by p-glycoprotein (p-gp), the same mechanism may prevent entry into the brain. In vitro, paclitaxel transport was examined in capillaries from rat brains by confocal microscopy using BODIPY Fl-paclitaxel. Western blots and immunostaining demonstrated apical expression of p-gp in isolated endothelial cells, vessels, and tissue. Secretion of BODIPY Fl-paclitaxel into capillary lumens was specific and energy-dependent. Steady state luminal fluorescence significantly exceeded cellular fluorescence and was reduced by NaCN, paclitaxel, and SDZ PSC-833 (valspodar), a p-gp blocker. Leukotriene C(4) (LTC(4)), an Mrp2-substrate, had no effect. Luminal accumulation of NBDL-cyclosporin, a p-gp substrate, was inhibited by paclitaxel. In vivo, paclitaxel levels in the brain, liver, kidney, and plasma of nude mice were determined after intravenous injection. Co-administration of valspodar led to increased paclitaxel levels in brains compared to monotherapy. Therapeutic relevance was proven for nude mice with implanted intracerebral human U-118 MG glioblastoma. Whereas paclitaxel did not affect tumor volume, co-administration of paclitaxel (intravenous) and PSC833 (peroral) reduced tumor volume by 90%. Thus, p-gp is an important obstacle preventing paclitaxel entry into the brain, and inhibition of this transporter allows the drug to reach sensitive tumors within the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Communication between Multiple Drug Binding Sites on P-glycoprotein
Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., & Callaghan, R. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12429-7 · Cited by 418
Xenobiotic Transport across Isolated Brain Microvessels Studied by Confocal Microscopy
Miller, D. S., Nobmann, S. N., Gutmann, H., Toeroek, M., Drewe, J., & Fricker, G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12708-3 · Cited by 307
Self-citationMolecular and Cellular Biology of Multidrug Resistance in Tumor Cells
(1991) · Springer eBooks · doi:10.1007/978-1-4615-3794-6 · Cited by 276
Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269
BEAULIEU, É., DEMEULE, M., GHITESCU, L., & BÉLIVEAU, R. (1997) · Biochemical Journal · doi:10.1042/bj3260539 · Cited by 253
Audus, K. L., & Borchardt, R. T. (1986) · Pharmaceutical Research · doi:10.1023/a:1016337202335 · Cited by 247
Zhang, Y., Han, H., Elmquist, W. F., & Miller, D. W. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02628-7 · Cited by 236
Self-citationvan Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A., Borst, P., Nooijen, W., & Beijnen, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.530 · Cited by 202
Drewe, J., Gutmann, H., Fricker, G., Török, M., Beglinger, C., & Huwyler, J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00026-x · Cited by 183
Self-citationAltered Pharmacokinetics of Vinblastine in Mdr1a P-glycoprotein-Deficient Mice
van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P., & van Tellingen, O. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.994 · Cited by 174
MDR1 gene expression in solid tumours
Goldstein, L. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00100-1 · Cited by 146
Ohnishi, T., Tamai, I., Sakanaka, K., Sakata, A., Yamashima, T., Yamashita, J., & Tsuji, A. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00082-b · Cited by 141
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD 2 F 1 mice
Eiseman, J. L., Eddington, N. D., Leslie, J. L., MacAuley, C., Sentz, D. L., Zuhowski, M., Kujawa, J. M., Young, D., & Egorin, M. J. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685656 · Cited by 139
Seetharaman, S., Barrand, M. A., Maskell, L. B., & Scheper, R. J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70031151.x · Cited by 137
Paclitaxel (TAXOL®) concentrations in brain tumor tissue
Heimans, J. J., Vermorken, J. B., Wolbers, J. G., Eeltink, C., Meijer, O. W. M., TAPHOORN, M. J. B., & Beijnen, J. H. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058736 · Cited by 131
Huwyler, J., Drewe, J., Klusemann, C., & Fricker, G. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15619.x · Cited by 123
Self-citationTóth, K., Vaughan, M. M., Peress, N. S., Slocum, H. K., & Rustum, Y. M. (1996) · PubMed Central · Cited by 114
Schramm, U., Fricker, G., Wenger, R. M., & Miller, D. S. (1995) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1995.268.1.f46 · Cited by 110
Self-citationRole of P‐Glycoprotein in the Blood‐Brain Transport of Colchicine and Vinblastine
Drion, N., Lemaire, M., Lefauconnier, J.-M., & Scherrmann, J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67041688.x · Cited by 104
DIAGNOSIS AND MANAGEMENT OF BRAIN METASTASES
Arnold, S. M., & Patchell, R. A. (2001) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70269-0 · Cited by 97
Expression of multidrug resistance protein gene in patients with glioma chemotherapy
Abe, T., Mori, T., Wakabayashi, Y., Nakagawa, M., Cole, S. P. C., Koike, K., Kuwano, M., & Hori, S. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005954406809 · Cited by 92
P-glycoprotein expression in brain tumors
Henson, J., Cordon‐Cardo, C., & Posner, J. B. (1992) · Journal of Neuro-Oncology · doi:10.1007/bf00170943 · Cited by 85
Fracasso, P. M., Westerveldt, P., Fears, C. L., Rosen, D. M., Zuhowski, E. G., Cazenave, L. A., Litchman, M., & Egorin, M. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1124 · Cited by 80
Sparreboom, A., van Tellingen, O., Noojien, W. J., & Beijnen, J. H. (1995) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(94)00495-q · Cited by 76
Gutmann, H., Török, M., Fricker, G., Huwyler, J., Beglinger, C., & Drewe, J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15245-2 · Cited by 67
Self-citationCurrent options in treatment of anthracycline-resistant breast cancer
Kröger, N. M., Achterrath, W., Hegewisch-Becker, S., Mross, K. B., & Zander, A. R. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0137 · Cited by 66
von Bossanyi, P., Diete, S., Dietzmann, K., Warich-Kirches, M., & Kirches, E. (1997) · Acta Neuropathologica · doi:10.1007/s004010050756 · Cited by 53
Sawada, T., Kato, Y., Sakayori, N., TAKEKAWA, Y., & Kobayashi, M. (1999) · Brain Tumor Pathology · doi:10.1007/bf02478898 · Cited by 51
Miller, D. S., & Pritchard, J. B. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.261.6.r1470 · Cited by 42
Self-citationThe role of paclitaxel in the treatment of primary and metastatic brain tumors.
Glantz, M., Chamberlain, M. C., Chang, S., Prados, M. D., & Cole, B. F. (1999) · PubMed · Cited by 37
Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer
Belani, C. P. (2000) · CHEST Journal · doi:10.1378/chest.117.4_suppl_1.144s · Cited by 31
Cited by
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 721
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Metadata
- Authors
- Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., Buschauer, A., & Fricker, G.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2002-11-01
- Volume
- 110
- Issue
- 9
- Pages
- 1309-1318
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2162592548
- Cited by
- 359
- References
- 35
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.